Optimize Fc, Albumin, and Fusion Protein-based Therapeutics to Address Autoantibody-Mediated Disorders
Enhance Our Understanding of FcRn’s Biology & MoA to Improve Clinical Success,
Maximize its Utility & Novel Therapeutic Applications
The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis, half-life extension, and recycling of human serum albumin and IgG, however in the case of more than 100+ rare and autoimmune disorders, this can not only be detrimental, but lethal to the health of the individual. Following the high profile J&J-Momenta deal, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020, other large players are poised to bring their candidates through the clinic in rapid succession.
The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases.
The 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body.
Join 100+ experts online from companies such as CSL Behring, Eli Lilly, Roche, Momenta, Alexion, Argenx and more to discuss FcRn MOA, preclinical model selection and translation, high throughput assays for ligand screening, IgG engineering, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.
World-Class Speaker Line-Up:
Some of Our Attendees Include:
“Invaluable opportunity to interact with thought leaders from academia and industry. This topic driven meeting provides a rare chance to have smaller, focused, scientific engagement that is increasingly difficult within large conferences”
“This is a well-balanced mix of speakers representing early and late drug development efforts and approaches that have worked and ones that have failed, we often only hear the success stories, but one can learn maybe even more from the failures”